Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00110524
Entity page: /trial/NCT04872790 ↗
Edges: 11

Neighbours: 3 cancers6 drugs
Drawn: 9 of 9 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia condition of …CONDITION_OFderived5 of 5
← condition of	B Acute Lymphoblastic Leukemia registry condition “B Acute Lymphoblastic Leukemia” mapped CURATED_BROADER	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
← condition of	B Acute Lymphoblastic Leukemia registry condition “Recurrent B Acute Lymphoblastic Leukemia” mapped CURATED_BROADER

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia intervention of …INTERVENTION_OFderived6 of 6
← intervention of	Blinatumomabmonoclonal antibody registry intervention “Blinatumomab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dasatinibsmall molecule registry intervention “Dasatinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Methotrexatesmall molecule registry intervention “Methotrexate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Prednisonesmall molecule registry intervention “Prednisone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rituximabmonoclonal antibody registry intervention “Rituximab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Venetoclaxsmall molecule registry intervention “Venetoclax” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia intervention of …INTERVENTION_OFderived6 of 6

← intervention of

Blinatumomabmonoclonal antibody

registry intervention “Blinatumomab” (BIOLOGICAL) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Dasatinibsmall molecule

registry intervention “Dasatinib” (DRUG) mapped ALIAS

—